Stock Performance and Market Context
On 30 June 2026, KIMS stock recorded an intraday high of Rs.825, representing a 2.42% gain on the day and outperforming its sector by 1.87%. The stock has been on a positive trajectory, registering gains for two consecutive days with a cumulative return of 3.6% during this period. This performance contrasts favourably against the broader Sensex, which declined by 0.26% on the same day.
Over various time frames, Krishna Institute of Medical Sciences Ltd has demonstrated robust returns. The stock’s one-month performance stands at 8.79%, significantly ahead of the Sensex’s 2.34%. Over three months, the stock surged by 32.52%, compared to the Sensex’s 6.36%. The year-to-date return is particularly impressive at 35.89%, while the Sensex has declined by 10.20% in the same period. Even over a five-year horizon, KIMS has delivered a remarkable 335.70% return, vastly outperforming the Sensex’s 45.81% gain.
Technical Indicators and Trend Analysis
The technical outlook for KIMS remains bullish, with the stock trading above all key moving averages including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. The overall technical trend shifted to bullish on 2 June 2026 at a price level of Rs.746.55, moving up from a mildly bullish stance. Key technical indicators such as MACD and Bollinger Bands support this positive momentum on the weekly scale, while monthly indicators present a mixed but generally constructive picture.
Immediate support is identified at Rs.575.55, the 52-week low, while resistance levels previously noted at Rs.782.10 (20-day moving average) and Rs.703.60 (100-day moving average) have been surpassed. The stock’s new 52-week high at Rs.825 now represents a far resistance level, underscoring the strength of the current rally.
Valuation Metrics
At the current price of Rs.825, Krishna Institute of Medical Sciences Ltd trades at a price-to-earnings (P/E) ratio of 136 times trailing twelve months earnings, reflecting a premium valuation consistent with its growth profile. The price-to-book value stands at 15.05 times, while enterprise value multiples include EV/EBITDA at 47.37 times and EV/EBIT at 73.24 times. The EV/Sales multiple is 9.73 times, and EV/Capital Employed is 5.93 times. Dividend metrics are not applicable as the company has not declared dividends recently.
Quality Assessment and Financial Health
KIMS is classified as a good quality company based on its long-term financial performance. The company’s management risk is rated good, with a capital structure also assessed favourably. Growth metrics are below average, but the company maintains a healthy sales compound annual growth rate (CAGR) of 24.04% over five years and an EBIT growth of 11.48% in the same period.
Return on capital employed (ROCE) averages a strong 20.10%, while return on equity (ROE) is a solid 17.81%. Institutional holdings are high at 47.07%, indicating significant participation by large investors. The company carries moderate leverage with an average debt-to-EBITDA ratio of 2.15 and a net debt-to-equity ratio of 1.85, reflecting a capital structure that balances growth with financial prudence.
Recent Financial Trends
In the short term, the company’s financial trend as of March 2026 shows some areas of concern. Quarterly net sales reached a peak of ₹1,074.60 crores, and PBDIT also hit a high of ₹206.50 crores. However, operating profit to interest coverage has declined to 3.03 times, and profit before tax excluding other income fell by 41.3% compared to the previous four-quarter average. Similarly, quarterly profit after tax decreased by 32.8% relative to the prior four-quarter average. The half-year ROCE dropped to 8.42%, while the debt-equity ratio rose to 1.89 times, indicating increased leverage. Interest expenses also increased to ₹68.10 crores, and earnings per share for the quarter declined to ₹1.06.
Volume and Market Capitalisation
Delivery volumes have shown a positive trend with a 1-month delivery change of 8.23% and a significant 23.29% increase in delivery volume on 29 June 2026 compared to the 5-day average. The stock is classified as a small-cap company based on its market capitalisation grade. On 29 June 2026, the delivery volume was 3.32 lakh shares, accounting for 54.51% of total volume, slightly below the 5-day average delivery percentage of 63.37%.
Summary of the Stock’s Journey
Krishna Institute of Medical Sciences Ltd’s ascent to an all-time high of Rs.825 is the culmination of sustained gains over multiple time frames and a strong technical foundation. The stock’s outperformance relative to the Sensex and its sector highlights its resilience and appeal within the hospital industry. While some short-term financial metrics indicate pressures, the company’s long-term quality indicators and institutional support underpin its current valuation and market standing.
This milestone reflects the company’s ability to maintain growth and investor confidence amid a competitive healthcare landscape, marking a significant chapter in its market journey.
